Rigmor Solberg
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Legumain is a paracrine regulator of osteoblast differentiation and mediates the inhibitory effect of TGF-β1 on osteoblast maturation.
Journal: Frontiers in endocrinology
Published: June 06, 2024
Interplay between Cultured Human Osteoblastic and Skeletal Muscle Cells: Effects of Conditioned Media on Glucose and Fatty Acid Metabolism.
Journal: Biomedicines
Published: September 12, 2023
The Mammalian Cysteine Protease Legumain in Health and Disease.
Journal: International journal of molecular sciences
Published: October 28, 2022
A Novel Porcine Model of Ischemia-Reperfusion Injury After Cross-Clamping the Thoracic Aorta Revealed Substantial Cardiopulmonary, Thromboinflammatory and Biochemical Changes Without Effect of C1-Inhibitor Treatment.
Journal: Frontiers in immunology
Published: January 11, 2022
Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Journal: Journal of the American Heart Association
Published: August 19, 2020
Legumain is upregulated in acute cardiovascular events and associated with improved outcome - potentially related to anti-inflammatory effects on macrophages.
Journal: Atherosclerosis
Published: April 15, 2019
Mammalian legumain - A lysosomal cysteine protease with extracellular functions?
Journal: Biochimie
Published: February 21, 2019
Lansoprazole inhibits the cysteine protease legumain by binding to the active site.
Journal: Basic & clinical pharmacology & toxicology
Published: December 19, 2018
Glycosylation is important for legumain localization and processing to active forms but not for cystatin E/M inhibitory functions.
Journal: Biochimie
Published: March 21, 2017
Last Updated: 09/26/2026